PL2094703T3 - Amidy diazabicykloalkanów selektywne wobec podtypu nikotynowego receptora acetylocholinowego - Google Patents

Amidy diazabicykloalkanów selektywne wobec podtypu nikotynowego receptora acetylocholinowego

Info

Publication number
PL2094703T3
PL2094703T3 PL07863786T PL07863786T PL2094703T3 PL 2094703 T3 PL2094703 T3 PL 2094703T3 PL 07863786 T PL07863786 T PL 07863786T PL 07863786 T PL07863786 T PL 07863786T PL 2094703 T3 PL2094703 T3 PL 2094703T3
Authority
PL
Poland
Prior art keywords
receptorsub
diazabicycloalkanes
nicotinic acetylcholine
type selective
amides
Prior art date
Application number
PL07863786T
Other languages
English (en)
Inventor
Anatoly Mazurov
Lan Miao
Yun-De Xiao
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PL2094703T3 publication Critical patent/PL2094703T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07863786T 2006-11-02 2007-11-01 Amidy diazabicykloalkanów selektywne wobec podtypu nikotynowego receptora acetylocholinowego PL2094703T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
EP07863786A EP2094703B1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
PL2094703T3 true PL2094703T3 (pl) 2011-10-31

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07863786T PL2094703T3 (pl) 2006-11-02 2007-11-01 Amidy diazabicykloalkanów selektywne wobec podtypu nikotynowego receptora acetylocholinowego

Country Status (33)

Country Link
US (6) US8114889B2 (pl)
EP (2) EP2094703B1 (pl)
JP (2) JP5539723B2 (pl)
KR (2) KR20100124356A (pl)
CN (4) CN102942569B (pl)
AR (2) AR063451A1 (pl)
AT (2) ATE545646T1 (pl)
AU (2) AU2007317433B2 (pl)
BR (2) BRPI0722387A2 (pl)
CA (1) CA2663925C (pl)
CL (1) CL2007003155A1 (pl)
CO (1) CO6180435A2 (pl)
CY (1) CY1112374T1 (pl)
DK (1) DK2094703T3 (pl)
ES (2) ES2395157T3 (pl)
HK (2) HK1133260A1 (pl)
HR (1) HRP20110570T1 (pl)
IL (2) IL197618A (pl)
MX (1) MX2009004801A (pl)
MY (2) MY156730A (pl)
NO (1) NO20091251L (pl)
NZ (2) NZ575557A (pl)
PE (2) PE20110671A1 (pl)
PL (1) PL2094703T3 (pl)
PT (1) PT2094703E (pl)
RS (1) RS51834B (pl)
RU (2) RU2448969C2 (pl)
SA (1) SA07280584B1 (pl)
SI (1) SI2094703T1 (pl)
TW (3) TWI454262B (pl)
UA (2) UA106718C2 (pl)
UY (1) UY30686A1 (pl)
WO (1) WO2008057938A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
RU2010140613A (ru) * 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
EP2344496A1 (en) * 2008-09-05 2011-07-20 Targacept Inc. Amides of diazabicyclooctanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
SI2899191T1 (sl) 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
HUE033352T2 (en) 2009-11-18 2017-11-28 Suven Life Sciences Ltd Bicyclic compounds as alpha4-beta2 nicotinic acetylcholine receptor ligands
KR101410903B1 (ko) 2009-12-29 2014-06-23 수벤 라이프 사이언시스 리미티드 α4β2 신경 니코틴성 아세틸콜린 수용체 리간드
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
MX2020004504A (es) 2015-09-04 2021-11-10 Hoffmann La Roche Derivados de fenoximetilo.
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
PE20180552A1 (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
KR102485299B1 (ko) 2016-04-07 2023-01-06 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
MD3448859T2 (ro) * 2017-03-20 2020-03-31 Forma Therapeutics Inc Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼrの活性化

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
PL179435B1 (pl) * 1993-12-29 2000-09-29 Pfizer Diazabicykliczni antagonisci neurokininy PL
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
AU1996301A (en) * 1999-12-14 2001-06-25 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
EP1406900B1 (en) * 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
BRPI0407216A (pt) * 2003-02-27 2006-01-24 Neurosearch As Derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
WO2005121145A2 (en) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
CA2574301C (en) 2004-07-22 2013-09-10 Cumbre Pharmaceuticals Inc. (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions
US20060258672A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
NO20091251L (no) 2009-05-28
ES2395157T3 (es) 2013-02-08
MX2009004801A (es) 2009-07-31
US9580434B2 (en) 2017-02-28
ES2395212T3 (es) 2013-02-11
NZ575557A (en) 2011-01-28
CN101528745B (zh) 2011-09-14
RU2009138600A (ru) 2011-04-27
TWI404532B (zh) 2013-08-11
JP5539723B2 (ja) 2014-07-02
SA07280584B1 (ar) 2010-11-02
AR063451A1 (es) 2009-01-28
IL209026A0 (en) 2011-01-31
AU2007317433B2 (en) 2012-05-10
ATE509022T1 (de) 2011-05-15
IL197618A0 (en) 2009-12-24
JP2010509230A (ja) 2010-03-25
US8268860B2 (en) 2012-09-18
CY1112374T1 (el) 2015-12-09
TWI405763B (zh) 2013-08-21
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
EP2284171B1 (en) 2012-02-15
CL2007003155A1 (es) 2008-05-16
UY30686A1 (es) 2009-08-03
HK1133260A1 (en) 2010-03-19
KR20100124356A (ko) 2010-11-26
US20150080576A1 (en) 2015-03-19
RS51834B (en) 2012-02-29
UA98944C2 (ru) 2012-07-10
NZ587847A (en) 2011-09-30
DK2094703T3 (da) 2011-08-29
BRPI0717930A2 (pt) 2011-05-10
TW201114424A (en) 2011-05-01
US8114889B2 (en) 2012-02-14
MY145602A (en) 2012-03-15
CN102942569B (zh) 2015-10-28
JP2013056919A (ja) 2013-03-28
PE20081441A1 (es) 2008-10-30
HK1149751A1 (en) 2011-10-14
RU2517693C2 (ru) 2014-05-27
BRPI0722387A2 (pt) 2023-02-23
SI2094703T1 (sl) 2011-07-29
PT2094703E (pt) 2011-07-22
CN102838605B (zh) 2017-04-26
US20120289572A1 (en) 2012-11-15
AR079840A2 (es) 2012-02-22
JP5739398B2 (ja) 2015-06-24
RU2009120674A (ru) 2010-12-10
CA2663925C (en) 2015-04-21
WO2008057938A1 (en) 2008-05-15
UA106718C2 (uk) 2014-10-10
MY156730A (en) 2016-03-15
ATE545646T1 (de) 2012-03-15
AU2010219323A1 (en) 2010-09-30
KR101415705B1 (ko) 2014-07-04
TWI454262B (zh) 2014-10-01
RU2448969C2 (ru) 2012-04-27
IL209026A (en) 2014-03-31
CO6180435A2 (es) 2010-07-19
CA2663925A1 (en) 2008-05-15
CN102942569A (zh) 2013-02-27
TW201305176A (zh) 2013-02-01
CN102838605A (zh) 2012-12-26
US8921410B2 (en) 2014-12-30
EP2094703B1 (en) 2011-05-11
AU2007317433A1 (en) 2008-05-15
US8859609B2 (en) 2014-10-14
EP2284171A1 (en) 2011-02-16
IL197618A (en) 2013-09-30
KR20090074051A (ko) 2009-07-03
US20100081683A1 (en) 2010-04-01
CN102020646B (zh) 2013-11-13
CN102020646A (zh) 2011-04-20
US20100173932A1 (en) 2010-07-08
PE20110671A1 (es) 2011-10-20
US20160039833A1 (en) 2016-02-11
TW200826935A (en) 2008-07-01
EP2094703A1 (en) 2009-09-02
HRP20110570T1 (hr) 2011-09-30
US20130005789A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
HK1133260A1 (en) Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
HUS000510I2 (hu) Oxatiapiprolin vagy N-oxidja vagy sója
HRP20130626T1 (en) Pyridinone compounds
IL227668A0 (en) Azadmantane derivatives and their uses as ligands for nicotinic acylcholine receptors
EP2000245A4 (en) WELDING PROCESS
DK2035004T3 (en) Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
HK1135090A1 (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
EP2082818A4 (en) RACK AND MANUFACTURING METHOD THEREFOR
IL196143A0 (en) Thiophene-sulfonic acid picolyl amides
EP2013903A4 (en) STRESSOR INTEGRATION AND METHOD THEREFOR
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
GB0705854D0 (en) Methods of construction
GB0608966D0 (en) Method and product
ZA200809112B (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
HK1128661A1 (en) Time recorder
GB0607488D0 (en) Composition and process
GB0605004D0 (en) Composition and process
GB0610059D0 (en) Uses and methods
GB0607493D0 (en) Composition and process
TWM298391U (en) Improved structure of bar
AU2012205208B2 (en) Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
IL194758A0 (en) N-oxides of pyridylmethylpipertazine and-piperidine derivatives
GB0622809D0 (en) Teaching aid
GB0624071D0 (en) Purification methods and materials
IL187936A0 (en) Joining device of passage block